Exact Goes All-In On Multi-Cancer Screening With $2.15Bn For Thrive; $410M For Base Genomics
Deals give the company access to technologies to increase the accuracy of multi-cancer blood tests.
You may also be interested in...
The addition of the Arizona-based sequencing lab builds on Exact’s recent license of the TARDIS liquid biopsy technology from TGen.
EY’s M&A Firepower report predicts very active M&A activity for medtechs in 2021, driven by diagnostics and digital health, but with some headwinds remaining.
JPM 2021: Intuitive Surgical, Accelerate Diagnostics, Siemens Healthineers, Exact Sciences, Renalytix
The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the third day of the meeting.